期刊文献+

HPLC法测定磷酸特地唑胺对映异构体 被引量:1

Determination of the Enantiomer of Tedizolid Phosphate by HPLC
下载PDF
导出
摘要 目的:建立了高效液相色谱法测定磷酸特地唑胺原料药对映异构体的方法。方法:采用CHIRALPAK■AGP(150 mm×4.0 mm,5μm)色谱柱,以磷酸二氢铵缓冲液为流动相A,以甲醇为流动相B,梯度洗脱,检测波长300 nm。结果:在该色谱条件下,特地唑胺和对映异构体之间的分离度均能达到1.5以上;对映异构体的检测限为相当于主成分浓度的0.02%;对映异构体在0.5~20μg/mL范围内线性良好,(r≥0.990,n=6);对映异构体的准确度在95.0%~100.0%之间,(RSD≤5.0)。结论:本方法可用于特地唑胺对映异构体的检测。 An HPLC method was established for the determination of enantiomer of tedizolid phosphate drug substance. Method:A CHIRALPAK■ AGP(150 mm×4.0 mm,5μm)was used. Ammonium dihydrogen phosphate buffer was used as mobile phase A and methanol as mobile phase B, Gradient elution with detection wavelength of 300 nm. Results:Under this chromatographic condition, the degree of separation between tedizolid phosphate and enantiomers can reach 1.5 or more;the detection limit ofenantiomers is equivalent to 0.02% of the main component concentration;The enantiomers were well linear in the range of 0.5~20 μg/mL( r≥0. 990,n=6). The accuracy of enantiomerswas between 95.0% and 100.0%(RSD≤5.0).Conclusion:The established method is suitablefor the determination of enantiomer of tedizolid phosphate.
作者 曾羽 刘运栋 Zeng Yu;Liu Yundong(College of Pharmaceutical Sciences,Soochow University,Jiangsu Suzhou 215000)
机构地区 苏州大学药学院
出处 《化工时刊》 CAS 2019年第10期9-11,共3页 Chemical Industry Times
关键词 磷酸特地唑胺 对映异构体 高效液相色谱 Tedizolid phosphate enantiomer HPLC
  • 相关文献

参考文献5

二级参考文献57

  • 1申睿,谢剑炜.手性选择剂及其在手性药物分离分析中的应用进展[J].国外医学(药学分册),2005,32(6):413-417. 被引量:10
  • 2Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections [J]. Expert Opin Investig Drugs, 2007, 16(2): 137-55. 被引量:1
  • 3Sood R, Bhadauriya T, Rao M, et al. Antimycobacterial activities of oxazolidinones: a review [J]. Infect Disord Drug Targets, 2006, 6(4): 343-54. 被引量:1
  • 4Howe RA, Woottonet M, Noel AR, et al. Activity of AZD2563, a novel oxazolidinone, against staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid[.l]. Antimicrob Agents Chemother, 2003, 47 (11): 3651-52. 被引量:1
  • 5Johnson AP. AZD-2563 AstraZeneca [J]. Curr Opin Investig Drugs, 2002, 3(6): 848-52. 被引量:1
  • 6Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci [J]. J Antimicrob Chemother, 2002, 50(2): 271-6. 被引量:1
  • 7Stockdale MW, Woodford N, Tysall L, et al. Low in vitro selection frequencies of enterococcal and Staphylococcal mutants resistant to the oxazolidinone AZD2563[J]. Int J Antimicrob Agents, 2004, 23(1): 88-91. 被引量:1
  • 8Kalia V, Miglani R, Raj VS, et al. Mode of action of Ranbezolid against Staphylococci and structural modeling studies of its interaction with ribosomes[J]. Antimicrob Agents Chemother, 2009, 53(4): 1427-33. 被引量:1
  • 9Das B, Rudra S, Yadav A, et al. Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid [J]. Bioorg Med Chem Lett, 2005, 15(19): 4261-7. 被引量:1
  • 10Yoon EJ, Jo YW, Choi SH, et al. In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria [J]. Antimicrob Agents Chemother, 2005, 49(6): 2498-500. 被引量:1

共引文献22

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部